Evaluating the Value of Health in Regulations
Author Information
Author(s): Weinhold Bob
Primary Institution: National Academies’ Institute of Medicine
Hypothesis
How should the value of health impacts be quantified in regulatory cost-effectiveness analysis?
Conclusion
The committee concluded that while cost-effectiveness analysis has its place, it has significant deficiencies that need to be addressed.
Supporting Evidence
- The committee made a dozen recommendations to improve cost-effectiveness analysis.
- Only 18 regulations met the criteria for cost-effectiveness analysis from January 2000 to June 2004.
- The committee emphasized the need for better data to support health impact measures.
Takeaway
This study looks at how we can put a price on health when making rules, but it says that this method isn't perfect and needs to be improved.
Methodology
The committee reviewed cost-effectiveness analysis methods and made recommendations for improvement.
Potential Biases
There is a risk that important health impacts that cannot be quantified may be overlooked.
Limitations
The study acknowledges that cost-effectiveness analysis is an imperfect tool and may not capture all health impacts accurately.
Participant Demographics
The committee included members from various U.S. and Canadian universities, health care systems, and state and federal agencies.
Want to read the original?
Access the complete publication on the publisher's website